These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 16817691)

  • 1. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.
    Xu Q; Liu G; Yuan X; Xu M; Wang H; Ji J; Konda B; Black KL; Yu JS
    Stem Cells; 2009 Aug; 27(8):1734-40. PubMed ID: 19536809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
    Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
    Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
    Zhang Z; Tang LL; Zhan RY; Tong Y; Yao HP; Du LA
    J Zhejiang Univ Sci; 2004 Oct; 5(10):1298-303. PubMed ID: 15362204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
    Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.
    Vik-Mo EO; Nyakas M; Mikkelsen BV; Moe MC; Due-Tønnesen P; Suso EM; Sæbøe-Larssen S; Sandberg C; Brinchmann JE; Helseth E; Rasmussen AM; Lote K; Aamdal S; Gaudernack G; Kvalheim G; Langmoen IA
    Cancer Immunol Immunother; 2013 Sep; 62(9):1499-509. PubMed ID: 23817721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
    Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
    J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
    Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
    Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
    Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
    Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma.
    Liu H; Chen L; Liu J; Meng H; Zhang R; Ma L; Wu L; Yu S; Shi F; Li Y; Zhang L; Wang L; Feng S; Zhang Q; Peng Y; Wu Q; Liu C; Chang X; Yang L; Uemura Y; Yu X; Liu T
    Cancer Lett; 2017 Dec; 411():182-190. PubMed ID: 28947140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
    Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
    J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
    Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
    Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.
    Okada H; Tahara H; Shurin MR; Attanucci J; Giezeman-Smits KM; Fellows WK; Lotze MT; Chambers WH; Bozik ME
    Int J Cancer; 1998 Oct; 78(2):196-201. PubMed ID: 9754652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.